Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShorTrip trial in locally advanced rectal cancer
2024-513297-21-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, oxaliplatin, levoleucovorin and irinotecan in rectal adenocarcinoma, sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Pathological complete response rate. Planned start Nov 2024; status: authorised.
02
Drugs
fluorouraciloxaliplatinlevoleucovorinirinotecan
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-513297-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513297-21-00.